Open AccessThis article is
- freely available
Allosteric Modulation of Muscarinic Acetylcholine Receptors
Institute of Physiology, Academy of Sciences of the Czech Republic, Vídeňská 1083, 142 00 Praha, Czech Republic
Division of Neuroscience Research in Psychiatry, University of Minnesota Medical School, Minneapolis, MN 55455, USA
* Authors to whom correspondence should be addressed.
Received: 8 July 2010; in revised form: 17 August 2010 / Accepted: 18 August 2010 / Published: 30 August 2010
Abstract: An allosteric modulator is a ligand that binds to an allosteric site on the receptor and changes receptor conformation to produce increase (positive cooperativity) or decrease (negative cooperativity) in the binding or action of an orthosteric agonist (e.g., acetylcholine). Since the identification of gallamine as the first allosteric modulator of muscarinic receptors in 1976, this unique mode of receptor modulation has been intensively studied by many groups. This review summarizes over 30 years of research on the molecular mechanisms of allosteric interactions of drugs with the receptor and for new allosteric modulators of muscarinic receptors with potential therapeutic use. Identification of positive modulators of acetylcholine binding and function that enhance neurotransmission and the discovery of highly selective allosteric modulators are mile-stones on the way to novel therapeutic agents for the treatment of schizophrenia, Alzheimer’s disease and other disorders involving impaired cognitive function.
Keywords: muscarinic acetylcholine receptors; allosteric modulation; Alzheimer’s disease; schizophrenia
Citations to this Article
Cite This Article
MDPI and ACS Style
Jakubík, J.; El-Fakahany, E.E. Allosteric Modulation of Muscarinic Acetylcholine Receptors. Pharmaceuticals 2010, 3, 2838-2860.
Jakubík J, El-Fakahany EE. Allosteric Modulation of Muscarinic Acetylcholine Receptors. Pharmaceuticals. 2010; 3(9):2838-2860.
Jakubík, Jan; El-Fakahany, Esam E. 2010. "Allosteric Modulation of Muscarinic Acetylcholine Receptors." Pharmaceuticals 3, no. 9: 2838-2860.